Skip to content

How I Practice: Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC
*Activity Post-Survey & Application for Credit*

In order to receive credit for this activity, you must read the front matter, view the activity, achieve a passing of at least 75% on this post-survey, as well as complete the linked evaluation and application for credit form. Certificates of credit will be emailed to participants who have successfully met these requirements.

There is no fee to participate in this activity.
1.What are your specialty & credentials?(Required.)
2.What is your community of practice?
3.Per NCCN guidelines, which of the following is a preferred first-line regimen for cisplatin eligible patients with mUC?(Required.)
4.Erdafitinib is recommended as a second-line treatment option for patients with which genetic alteration?(Required.)
5.75yo woman with newly diagnosed PD-L1 positive mUC has a GFR of 25mL/min. According to the EAU guidelines, which of the following would be an appropriate 1L treatment option for her?(Required.)
6.A 77-year-old man with mUC and no identifiable genetic alterations receives 1L EV+P and 2L gem + cis. He presents 9 months after completing 2L treatment with progressive disease. Which of the following would be an appropriate 3L treatment for him based on NCCN guidelines?(Required.)
EVALUATION FORM
7.Upon completion of this activity, I am able to:
Strongly agree
Agree
Disagree
Strongly disagree
DESCRIBE efficacy data regarding standard therapies used in the treatment of metastatic urothelial carcinoma
SELECT appropriate treatment based on the latest guidelines regarding preferred treatment regimens for metastatic urothelial carcinoma
8.Please indicate the extent of your agreement with the following statements: 
Strongly agree
Agree
Disagree
Strongly disagree
The faculty for this activity were effective
9.Overall, was this activity fair, balanced and free from commercial bias?
10.If no, please explain:
11.Of the patients you will see in the next month, about how many will benefit from the information you learned today?
12.Based on what I learned today, I will improve my practice by incorporating the following (check all that apply):
13.Based on your experience, which of the following are the primary barriers to implementing changes in practice (check all that apply):
14.For purposes of certification, please complete the following information. *Please note that we will not forward or sell your contact information.*(Required.)
15.I certify that I have participated in the continuing education activity entitled, "How I Practice : Role of Treatment Guidelines in Therapy Selection & Sequencing for mUC" and claim 0.5 AMA PRA Category 1 CreditTM.(Required.)
Thank you for participating in our activity and completing the necessary paperwork. Your certificate will be emailed to you using the email address provided above. Please allow 4 weeks to receive your certificate.

For additional information about the accreditation of this activity, please visit https://www.partnersed.com
Privacy & Cookie Notice